Compare FET & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | AURA |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.2M | 797.5M |
| IPO Year | 2007 | 2021 |
| Metric | FET | AURA |
|---|---|---|
| Price | $80.95 | $6.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 154.3K | ★ 628.3K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $791,474,000.00 | N/A |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $207.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.07 | $4.73 |
| 52 Week High | $87.42 | $9.54 |
| Indicator | FET | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 29.62 |
| Support Level | $75.68 | $6.10 |
| Resistance Level | $85.79 | $6.69 |
| Average True Range (ATR) | 3.26 | 0.32 |
| MACD | -0.64 | -0.11 |
| Stochastic Oscillator | 59.58 | 8.10 |
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.